Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Ranbaxy Laboratories Stories

2008-09-05 12:00:27

Speaking before reporters at one of New Delhi's poshest hotels last month, Ranbaxy Laboratories (RANB.BO) CEO and Chairman Malvinder M. Singh was all smiles. Even though his family's company, India's largest drug manufacturer, had seen its profits plunge 91% from the previous quarter because of the volatile Indian currency, Singh had reason to be upbeat. Ranbaxy was in the process of finishing a merger with Tokyo-based Daiichi Sankyo (4568.T), a $4.6 billion deal [BusinessWeek.com, 6/11/08]...

2008-07-29 09:01:14

Ranbaxy Pharmaceuticals, a wholly owned subsidiary of Ranbaxy Laboratories, Gurgaon, India, has announced that under an agreement with AstraZeneca Pharmaceuticals it has launched an authorized generic of Omeprazole 40mg capsules in the US healthcare system. Ranbaxy's Omeprazole 40mg is indicated for the treatment of acid-related disease, including gastric ulcer and Zollinger-Ellison syndrome. Jim Meehan, vice president of sales and distribution at Ranbaxy Pharmaceuticals, said: "We...

2008-07-28 12:01:07

GURGAON, India and PRINCETON, N.J., July 28 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, India announced today that under an agreement with AstraZeneca Pharmaceuticals it has launched an authorized generic of Omeprazole 40 mg Capsules in the U.S. healthcare system. Omeprazole 40 mg is indicated for the treatment of acid-related disease, including gastric ulcer and Zollinger-Ellison syndrome. The most common...

2008-07-22 06:00:45

Research and Markets (http://www.researchandmarkets.com/research/70a734/india_pharmaceutic) has announced the addition of the "India Pharmaceuticals and Healthcare Report Q3 2008" report to their offering. This report provides independent forecasts and competitive intelligence on India's pharmaceuticals and healthcare industry. Multinationals continue to exhibit their interest in the market. For example, Israeli generic giant Teva is planning to use India for active pharmaceutical...

2008-07-19 09:00:17

By Alistair Dawber The increase in merger deals involving generic drug companies has continued apace after Israel's Teva Pharmaceuticals announced it was buying its American rival Barr, the fourth-biggest group in the sector, for $7.5bn (3.75bn). The friendly deal will combine the generalist group Teva with Barr, which specialises in female healthcare, giving the merged company more than 500 products and sales worth $11.9bn. Teva will pay $66.50 for each share, which represents a 32 per...

2008-06-19 09:00:42

DALLAS | Airlines executives are continuing to cut jobs and consider new fees on passengers as they battle high fuel prices. Executives from United Airlines gave more details on plans to shed up to 1,600 salaried jobs at an investors' conference in New York on Wednesday. Chief Financial Officer Jake Brace said United will also cut union jobs - pilots, flight attendants and mechanics - once the airline draws up a scaled-back flying schedule for fall and winter. Delta Air Lines Inc. said it...

2008-02-13 11:00:00

Patches sold in the United States under the brand name Duragesic which contain the painkiller fentanyl were recalled on Tuesday.The recall includes all 25-microgram-per-hour patches that have expiration dates on or before December 2009.The cause of the recall is a possible cut in the lining of the reservoir where the drug is stored in gel form. A gel leak into the drug's packaging could result in difficulty breathing and a potentially fatal overdose.The cut in the patch can be seen when the...

2007-10-29 12:00:47

India's Ranbaxy Laboratories has received tentative approval from the FDA to market four dosage strenghs of valsartan, a generic version of Novartis's hypertension drug Diovan. Valsartan is indicated for the treatment of hypertension alone or in combination with other anti-hypertensive agents. Valsartan is also indicated for the treatment of heart failure. Jim Meehan, vice president of sales and distribution for Ranbaxy Pharmaceuticals, said: "We are pleased to receive tentative approval...

2006-07-25 00:57:38

By Irwin Arieff UNITED NATIONS (Reuters) - U.N. Secretary-General Kofi Annan encouraged executives from nine drug companies on Monday to lower prices of AIDS medicines and step up efforts to develop AIDS drugs and diagnostics for children. Annan for the first time included generic drug makers in his latest in a series of meetings with top drug makers at U.N. headquarters over the past five years. The meetings aim to encourage the pharmaceutical firms to broaden access to AIDS drugs,...

2006-03-20 10:35:00

By Ben Hirschler, European Pharmaceuticals Correspondent LONDON -- China will leapfrog Britain and Italy to become the world's fifth most valuable pharmaceuticals market by 2010, industry experts said on Monday. Melanie Lee of Boston Consulting Group predicted Chinese drug sales would virtually double to $25 billion a year from $13 billion in 2005, driven by greater adoption of Western-style medicines. Such products currently account for less than a quarter of a market dominated by locally...